Osteotech Reports Third Quarter 2009 Financi...(rences in anticipated and actual product...),Health

Date:11/5/2009

rences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 5, 2009 and the Company does not intend to update this information.

                              OSTEOTECH, INC. and Subsidiaries
                           CONSOLIDATED STATEMENTS OF OPERATIONS
                       (dollars in thousands, except per share data)
                                         (unaudited)


                               Three Months         Nine Months
                                   Ended               Ended
                               September 30,        September 30,
                             2009       2008       2009       2008

    Revenue               $22,961    $24,063    $70,363    $79,247
    Cost of Revenue        12,502     11,182     36,406     37,622
    Gross profit           10,459     12,881     33,957     41,625

    Marketing, selling and
      general and
      administrative
      expenses             10,648     10,476     33,034     33,479
    Research and
      development
      expenses              1,544      1,739      5,195      5,273
                           12,192     12,215     38,229     38,752

    Operating income
     (loss)                (1,733)       666     (4,272)     2,873

    Interest expense,
      net                    (354)     (276)     (1,063)      (762)
    Other                      58      (270)        106        953

    Income before
      income taxes         (2,029)       120     (5,22
'/>"/>
SOURCE  Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
4. Air Methods Reports 3Q2009 Results and 4Q2009 Update
5. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
8. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
9. PDI Reports 2009 Third Quarter Financial Results
10. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
11. Symmetry Medical Reports Third Quarter 2009 Financial Results